Key facts
- This page summarizes Eric E. Poma's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Aug 2025, 20:47.
Eric E. Poma - 25 Aug 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CLDI
- Reported as of
- 25 Aug 2025
- Net transaction value
- +$50,000
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2025, 20:47:39 UTC
- Prior SEC filing
- 25 Apr 2025
- Next SEC filing
- 05 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Jackson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric E. Poma filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 25 Aug 2025.
Change
- Previous filing in this sequence was filed on 25 Apr 2025.
- Current net transaction value: +$50,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001339484
Primary reporting owner
Poma Eric E
- Relationship
- Chief Executive Officer, Director
- Address
- C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
- Signature
- /s/ Andrew Jackson, Attorney-in-fact
- Signature date
- 25 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDI
transaction
Common Stock
Purchase
- Transaction value
- $50,000
- Shares
- +25,000
- Change %
- Price
- $2.00*
- Shares after
- 25,000
- Date
- 21 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDI
transaction
Derivative
Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 21 Aug 2025
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 25,000
- Exercise price
- $2.00
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.
Footnote F2
Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.
SEC remarks
Exhibit 24 - Power of Attorney